Results 211 to 220 of about 9,423,446 (404)

Speech therapy for patients with Parkinson's disease. [PDF]

, 1981
Sheila Scott, F. I. Caird
openalex   +1 more source

Hemihypomimia in Parkinson's disease [PDF]

, 2005
Brandt, T., Jahn, K., Strupp, M., Zingler, V. C.   +3 more
core   +1 more source

Bilirubin Targeting WNK1 to Alleviate NLRP3‐Mediated Neuroinflammation

Advanced Science, EarlyView.
At physiological concentrations, bilirubin binds to the kinase domain of WNK1, thereby augmenting its activity and facilitating the phosphorylation of downstream SPAK/OSR1. This phosphorylation inhibits KCC2 activity, leading to elevate intracellular chloride levels in neurons.
Linfei Mao, Jiayu Lu, Quanjun Yang, Zhenqi Liu, Cuiping Wu, Bingbing Ke, Kaiyan Su, Haolin Yuan, Yaqi Cui, Yao Wang, Richard Salvi, Guang Yang, Shankai Yin, Feng Liu, Chunyan Li   +14 more
wiley   +1 more source

The blood–brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates—Evidence from in vivo neuroimaging studies

Neurobiology of Disease, 2009
It has been suggested, based on rodent studies, that levodopa (l-dopa) induced dyskinesia is associated with a disrupted blood–brain barrier (BBB). We have investigated BBB integrity with in vivo neuroimaging techniques in six 1-methyl-4-phenyl-1,2,3,6 ...
Arnar Astradsson, Bruce G. Jenkins, Ji-Kyung Choi, Penelope J. Hallett, Michele A. Levesque, Jack S. McDowell, Anna-Liisa Brownell, Roger D. Spealman, Ole Isacson   +8 more
doaj  

Resolution of dyskinesia and the "on-off" phenomenon in thyrotoxic patients with Parkinson's disease after antithyroid treatment. [PDF]

, 1986
T. H. Caradoc‐Davies
openalex   +1 more source

Challenges in the diagnosis of Parkinson's disease

Lancet Neurology, 2021
E. Tolosa, Alicia Garrido, Sonja W. Scholz, W. Poewe   +3 more
semanticscholar   +1 more source

NAD+‐Boosters Improve Mitochondria Quality Control In Parkinson's Disease Models Via Mitochondrial UPR

Advanced Science, EarlyView.
Treatment of MPTP‐incubated cells with NAD+‐boosters increase the UPRmt/mitophagy‐related mitochondria quality control (MQC). Disturbed plasma UPRmt‐mitophagy‐mediated MQC profiles in PD patient samples. NMN inhibits motor deficit and forestalls neuropathology phenotypes of PD mice, which is required the atf4‐medicated UPRmt pathway.
Shuoting Zhou, Xi Xiong, Jialong Hou, Qi Duan, Yi Zheng, Tao Jiang, Jiani Huang, Haijun He, Jiaxue Xu, Keke Chen, Wenwen Wang, Jinlai Cai, Jingjing Qian, Huijun Chen, Weihong Song, XinShi Wang, Chenglong Xie   +16 more
wiley   +1 more source

Continuous Dopaminergic Stimulation in Parkinson's Disease [PDF]

, 1987
José Á. Obeso, M. R. Luquín, J. Vaamonde, Francisco Grandas, J. Manuel Martínez Lage   +4 more
openalex   +1 more source

Single Administration of AAV‐mAtp6v1b2 Gene Therapy Rescues Hearing and Vestibular Disorders Caused by Atp6v1b2‐Induced Lysosomal Dysfunction in Hair Cells

Advanced Science, EarlyView.
Wei et al. establish a hair cell‐specific conditional knockout mouse model (Atp6v1b2fl/fl;Atoh1Cre/+), and demonstrate the importance of Atp6v1b2 for hair cell through maintaining the survival of lysosomes. A single administration of AAV‐ie‐Eh3‐mAtp6v1b2 through scala media at P0‐P2 realizes function compensation and restores hearing and balance ...
Gege Wei, Shiwei Qiu, Xue Gao, Lu Zheng, Yijin Chen, Ying Ma, Haifeng Feng, Jinyuan Yang, Guojie Dong, Huiyi Nie, Weihao Zhao, Xiaoge Li, Guangqin Wang, Wei Xiong, Pu Dai, Yongyi Yuan   +15 more
wiley   +1 more source

Sebaceous Gland Secretion in Parkinson's Disease During L-Dopa Treatment

, 1973
Steven R. Kohn, Peter E. Pochi, John S. Strauss, Daniel S. Sax, Robert G. Feldman, William H. Timberlake   +5 more
openalex   +1 more source